Evidence map›Paper›PMID 41891499›Full record

ArticleAdvanced healthcare materials2026

Deciphering the Role of Cancer Stem Cells in Breast Cancer Brain Colonization Using a Novel Patient-Derived Model.

Stefania Faletti, Cristina Richichi, Daniela Osti, Elena Ceccacci, Giovanni Bertalot, Camilla Cerutti, Giuseppina Giardina, Adriana Marinaro, Brunella Costanza, Valentina Gambino and 18 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Stefania FalettiDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Cristina RichichiDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Daniela OstiDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Elena CeccacciDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Giovanni BertalotDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Camilla CeruttiDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Giuseppina GiardinaDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Adriana MarinaroDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.ORCID https://orcid.org/0009-0008-1897-0474
Brunella CostanzaDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Valentina GambinoDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Elena ZaccheroniDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Daniela TosoniDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Maria G FilipponeDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Marcello Del CorvoDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Yinxiu ZhanDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Teresa GravinaDepartment of Translational Medicine, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale, Novara, Italy.
Davide CoràDepartment of Translational Medicine, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale, Novara, Italy.
Monica PatanèNeuropathology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Bianca PolloNeuropathology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Maria Giovanna JodiceDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Salvatore PeceDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Babette B WekslerDepartment of Medicine, Weill Medical College of Cornell University, New York, United States.
Ignacio A RomeroDepartment of Biological Sciences, The Open University, Milton Keynes, United Kingdom.
Pierre-Olivier CouraudInstitut Cochin, Centre National de la Recherche Scientifique UMR 8104, Institut National de la Santé et de la Recherche Médicale (INSERM) U567, Université René Descartes, Paris, France.
Elisabetta MunzoneDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.
Massimiliano Del BeneDepartment of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Francesco DiMecoDepartment of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
Giuliana PelicciDepartment of Experimental Oncology, IRCCS, European Institute of Oncology (IEO), Milan, Italy.ORCID https://orcid.org/0000-0003-0986-8255

Funding

Italian Association for Cancer Research 27014
6 · The paper itself

Abstract

Brain metastases from breast cancer (BCBM) are fatal and lack effective treatments. Their cellular and molecular drivers remain poorly understood, partly due to limited preclinical models that fail to capture patient tumor heterogeneity. Cancer stem-like cells (CSCs) are implicated in metastatic dissemination; however, their specific role in brain metastasis remains unclear. In this study, CSCs are isolated from human BCBM specimens and characterized for stem-like properties, including CD44 and ALDH1 expression, sphere formation, tumorigenicity, and in vitro and in vivo self-renewal. Intra-nipple and intra-cardiac xenograft models demonstrate CSC ability to generate brain and bone metastases that recapitulate patient-specific dissemination patterns. Transcriptomic and functional analyses reveal cellular heterogeneity and identify a metastasis-initiating cell (MIC) subpopulation enriched in stemness and adhesion-related pathways. These MICs exhibit enhanced adhesion to brain endothelium and undergo brain-specific transcriptomic reprogramming that enables vascular co-option, resistance to stromal stress, and survival-promoting interactions with brain-resident cells. High-throughput drug screening indicates broad therapeutic resistance within the CSC compartment. Through the comprehensive characterization of BCBM-derived CSCs, this study establishes a clinically relevant model that identifies CSCs and the MIC subpopulation as key drivers of brain metastatic progression and as promising targets for the development of effective therapeutic strategies.

Indexed as

Brain NeoplasmsBreast NeoplasmsNeoplastic Stem CellsAldehyde Dehydrogenase 1 FamilyAnimalsCell Line, TumorFemaleHumansHyaluronan ReceptorsMiceAldehyde Dehydrogenase 1 FamilyHyaluronan Receptorsbrain metastasisbreast cancercancer stem cellsmetastasis initiating cellspreclinical model

Identifiers

PMID41891499
PMCPMC13206392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.